The Indian company claims that the preparation can be given to adults and children as young as 12 years old.
The ZyCoV-D vaccine uses a piece of the virus’ genetic material that relays instructions to make a specific protein that the immune system recognizes and responds to.
Unlike most Covid-19 vaccines, which require one or two doses, ZyCoV-D is given as three doses.
The manufacturer announced in July that its preparation is effective against new strains of coronavirus and is administered using a needle-free syringe. It intends to produce 100 to 120 million doses of ZyCoV-D annually.
The company applied for a license for ZyCoV-D on July 1, based on a 66.6 percent success rate. In a late study that included more than 28,000 volunteers, including a thousand. They are children between the ages of 12 and 18. ZyCoV-D is the sixth vaccine approved for use in India.
On Monday, Quartz said the Indian government had approved the vaccine for the second time without data from phase 3 clinical trials. The first vaccine approved in this way was Covaxin from India’s Bharat Biotech. As Quartz added, no data on the effectiveness of ZyCoV-D is publicly available in a published study.
We are glad you are with us. Subscribe to the Onet newsletter to receive the most valuable content from us
Date created: Today 14:04
“Coffee enthusiast. Troublemaker. Incurable introvert. Subtly charming twitter scholar. Award-winning social mediaholic. Internet buff.”